Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been
studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable …

Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the
discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal …

Lung carcinoma is one of the most common cancers and has one of the lowest survival rates
in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable …

Synthetic gene circuits that precisely control human cell function could expand the
capabilities of gene-and cell-based therapies. However, platforms for developing circuits in …

Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …

Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …